Prime Capital Investment Advisors LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 52.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,163 shares of the company’s stock after selling 25,566 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Johnson & Johnson were worth $3,449,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Morgan Stanley boosted its stake in Johnson & Johnson by 0.3% in the 1st quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock valued at $2,727,694,000 after buying an additional 54,563 shares in the last quarter. Price Wealth LLC raised its stake in Johnson & Johnson by 8.6% during the second quarter. Price Wealth LLC now owns 1,270 shares of the company’s stock worth $179,000 after acquiring an additional 101 shares in the last quarter. Financial Advisory Service Inc. lifted its holdings in shares of Johnson & Johnson by 2.5% during the second quarter. Financial Advisory Service Inc. now owns 17,970 shares of the company’s stock valued at $2,527,000 after acquiring an additional 431 shares during the period. Abundance Wealth Counselors boosted its stake in shares of Johnson & Johnson by 183.3% in the 2nd quarter. Abundance Wealth Counselors now owns 7,109 shares of the company’s stock valued at $1,000,000 after purchasing an additional 4,600 shares in the last quarter. Finally, Adams Asset Advisors LLC grew its holdings in shares of Johnson & Johnson by 178.6% in the 2nd quarter. Adams Asset Advisors LLC now owns 15,980 shares of the company’s stock worth $2,247,000 after purchasing an additional 10,245 shares during the last quarter. 67.44% of the stock is currently owned by institutional investors and hedge funds.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.27% of the company’s stock.
A number of equities analysts have commented on JNJ shares. Stifel Nicolaus lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Cantor Fitzgerald boosted their target price on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. Credit Suisse Group increased their price target on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 14th. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $164.93.
Shares of NYSE JNJ opened at $146.36 on Friday. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00. The firm’s 50-day moving average is $145.51 and its 200-day moving average is $146.57. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $385.30 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.22. The firm had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The business’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same period last year, the firm earned $2.12 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a dividend of $1.01 per share. The ex-dividend date is Monday, November 23rd. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.76%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Story: How to calculate compound interest
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.